|
19-5-2022 12:15 EDT
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
17-5-2022 14:43 EDT
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
12-5-2022 1:30 EDT
| Three-month interim report (Q1) 2022 |
|
3-5-2022 5:29 EDT
| Release date of three-month interim report (Q1) 2022 for ALK and audio cast |
|
29-3-2022 4:30 EDT
| Total share capital and voting rights |
|
24-3-2022 12:15 EDT
| Grant of share options and performance shares to members of the Board of Management and key employees |
|
16-3-2022 14:18 EDT
| Decision to complete share split at a ratio of 1:20 |
|
16-3-2022 12:58 EDT
| Annual General Meeting in ALK-Abelló A/S held on 16 March 2022 |
|
3-3-2022 6:33 EST
| Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet |
|
2-3-2022 11:03 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
21-2-2022 8:00 EST
| Annual General Meeting in ALK-Abelló A/S on 16 March 2022 |
|
8-2-2022 1:29 EST
| Annual report 2021: ALK delivers strong sales growth of 12% with tablet sales up 29% and EBITDA up 35% |
|
3-2-2022 3:40 EST
| Release date of annual report 2021 for ALK and audio cast |
